


**FAST  
RESULTS**



**REALTIME PCR**



**RELIABLE SERVICE**



# BioCentra®

Enhancing Delivery of Care Through Next-Gen Laboratory Diagnostics

# A Trusted Partner

**Proficiency in Testing:** Delivering reliable results for a wide range of high-complexity tests.

**Advanced Technology:** Leveraging cutting-edge tools for precision diagnostics.

**Provider Trust:** Built on consistent quality and integrity.

**Patient Privacy:** Ensuring data confidentiality with robust security measures.

**Partner Collaboration:** Working seamlessly with providers and reference lab partners to enhance care delivery

**Technology Innovation:** Consistently developing and validating new diagnostics tests to improve availability and cost effectiveness.

01

## Mission

Revolutionizing patient care and satisfaction through accurate, timely, and personalized diagnostics.

02

## Commitment

Dedicated to supporting primary care physicians in delivering superior patient care through precision diagnostics.

03

## Vision

Empowering physicians achieve greater patient satisfaction with tools that simplify treatment decisions thereby elevating standards of care.



Elevating Quality of Care Through Next-Gen Lab Testing

# Key Members

We are always prepared to collaborate and to provide necessary technical, medical, and strategic assistance to foster the growth of both our businesses.



**Dr. Javid Wani, Ph.D.**  
Lab Director & CEO




**Brian Cervenka, BS**  
Operations Manager




**Xi Luo, Ph.D., ABMGG**  
Clinical Director



**Dr. Mirza Beg, MD**  
**Neuro-Psychiatrist**  
Medical Director



**Omar Masihuddin, PA**  
**Neurology & Gen. Med.**  
Clinical Liaison



**Lilia Othman, BS**  
Lab Manager



Elevating Quality of Care Through Next-Gen Lab Testing

# Our Lab

BioCentra LLC established in 2008 is a CAP and CLIA accredited high-complexity molecular diagnostics laboratory serving patients in North America.

Our cutting-edge technology allows us to perform complex diagnostic assays with exceptional precision, delivering results quickly and accommodating a wide variety of human sample types.



COLLEGE of AMERICAN  
PATHOLOGISTS

## CERTIFICATE OF ACCREDITATION

**BioCentra LLC**  
**Laboratory**  
**Houston, Texas**  
**Xi Luo, PhD, ABMGG, ACMG**

CAP#: 9518360  
CLIA#: 45D2237827

The organization named above meets all applicable standards for accreditation and is hereby accredited by the College of American Pathologists' Laboratory Accreditation Program. Reinspection should occur prior to **May 09, 2027** to maintain accreditation.

Accreditation does not automatically survive a change in director, ownership, or location and assumes that all interim requirements are met.

Kathleen G. Beavis, MD  
Chair, Accreditation Committee


Donald S. Karcher, MD, FCAP  
President, College of American Pathologists



**BioCentra**  
Diagnostics™




Clinical  
Laboratory  
Improvement  
Amendments






Molecular  
Infectious Diseases

Featured Diagnostics Testing Panels




**RPP Pathogen Panel with Reflex to ABDR**

RPP Panel detects 28 Pathogens and 26 antibiotic resistance genes.



**STI Pathogen Panel with Reflex to ABDR**

Detects 2 bacterial, 6 viral, 6 fungal pathogens & 26 antibiotic resistance genes.



**UTI Pathogen Panel with Reflex to ABDR**


Detects 24 bacteria/ fungi and 26 antibiotic resistance genes.

Dementia, TBI and  
Cardiovascular Diseases



**CogScan® Dementia and Alzheimer's Disease Test**

Genetic Test to Determine the Risk for Dementia or Alzheimer's Disease.



**TBioScan® Traumatic Brain Injury Essential Test**

Next-Gen Tool for Diagnosing Mild Traumatic Brain Injuries.



**CardioScan® Cardiovascular Disease Risk Test**

CardioScan® identifies individuals with elevated risk for CVD.

# Clinical Impact

Contemporary diagnostic technologies, when combined with treatment guidance, significantly enhance the clinical impact of healthcare providers. This enables them to effectively navigate care and collaborate with essential support services when necessary.

01

**Molecular Pathogen Panel testing** is essential to **hospitals, clinics, nursing home, and short-term care** facilities for **infectious diseases** diagnoses and to guide **antibiotic treatment** decisions.

02

Genetic testing for **dementia and cardiovascular disease** will establish early risk and guide care.

03

95% of **mild Traumatic Brain Injuries** (mTBI/ concussion) are often missed by CT/MRI imaging. Our **TBioScan®** range of diagnostics will solve this problem by covering **personal injury and sports** industry.

# Secure Infotech

Our exclusive LIMS System provides clients with secure, real-time access to patient data for seamless registration, scheduling, and reporting.

- **Real-Time Access:** BioCentra LIMS provides physicians with real-time access to diagnostic reports for prompt decision-making.
- **Customized Interface:** User-friendly design tailored to healthcare providers for easy navigation through EHR's like AthenaOne and eClinicalWorks.
- **Secure Data Handling:** Ensures confidentiality and integrity of patient information.
- **Enhanced Communication:** Direct connection between physicians and our lab team for better coordination.
- **Comprehensive Support:** From onboarding and training to ongoing updates and assistance.



# Example ID Report

1. **Enhanced Patient Care:** Empower physicians with timely, accurate diagnostics to deliver personalized treatment plans, improving satisfaction and boosting practice revenues.
2. **Easy to Understand:** Clear and concise reports aid quick comprehension for physicians.
3. **Time-Saving:** Physicians save time with efficient report interpretation.
4. **Antibiotics Recommendation:** Reports recommend appropriate antibiotics and dosages thereof.
5. **Fully Automated:** Automated process ensures rapid and reliable report delivery and review by physicians.
6. **No Need of Specialist Referrals:** PCP's are empowered to correctly treat 99% of the uncomplicated infections without having to refer to the next level of care.

Patient ID	Specimen Type	Patient First Name	Patient Last Name
P-126	NP Swab		Male
Referring Provider	Provider NPI	Date of Service	Patient DOB
MD		12/1/23	

PHATOGENS DETECTED	POSITIVE RESULTS	RESPIRATORY PATHOGEN PANEL - VIRUSES	PNEUMONIA PATHOGEN PANEL - BACTERIA
	Haemophilus influenzae Moraxella catarrhalis Klebsiella aerogenes	SARS-CoV-2 Respiratory Syncytial Viruses A/B Influenza A Influenza B Human Metapneumovirus (hMPV) Human Adenovirus Human Rhinovirus Haemophilus influenzae Human Parainfluenza 1 Human Parainfluenza 2 Human Parainfluenza 3 Human Parainfluenza 4	Moraxella catarrhalis Pseudomonas aeruginosa Serratia marcescens Streptococcus agalactiae Legionella pneumophila Klebsiella pneumonia Mycoplasma pneumoniae Staphylococcus aureus Chlamydia pneumoniae Streptococcus pneumoniae Klebsiella aerogenes Streptococcus pyogenes
ANTIBIOTIC RESISTANCE DETECTED	POSITIVE RESULTS	ANTIBIOTIC RESISTANCE PANEL - GENES TESTED	
	Macrolide Methicillin/Oxacillin Sulfonamides	Class A beta-lactamase (CTX-M) Class A beta-lactamase (SHV/KPC) Class D beta-lactamase (OXA48/OXA51) Fluoroquinolones (QnrA1&2/QnrB/QnrS) Macrolide/ Lincosamide/ Streptogramin (ermA/B/C)	Macrolide (MefA) Methicillin/Oxacillin (mecA) Sulfonamides (Sul 1/Sul 2/Sul 3) Trimethoprim (dfrA1/dfrA5) Vancomycin (A/B)
TREATMENT RECOMMENDATION	Ciprofloxacin	RECOMMENDED DOSAGE	
		500 mg orally twice a day for 7 days.	
POST-DIAGNOSTICS OBSERVATIONS	Bacterial Infection	CLINICAL MANIFESTATIONS	
		The gram-negative bacteria like Haemophilus, Klebsiella, and Moraxella species cause numerous mild and serious infections, including bacteremia, meningitis, pneumonia, sinusitis, otitis media, cellulitis, and epiglottitis.	

Date of Release:	12/6/23	Approved By:	Javid Wani, Ph.D.
------------------	---------	--------------	-------------------

**Note:** This test was developed, and its analytical performance characteristics have been determined by BioCentra Diagnostics. It has not been cleared or approved by the FDA. This assay has been developed and validated pursuant to the CLIA regulations and can be used for clinical purposes. The analytical performance of this assay meets the quality and regulatory standards of clinical testing regulations.



Elevating Quality of Care Through Next-Gen Lab Testing

# Comprehensive Services & Patient-Centered Care



**BioCentra**  
Diagnostics™

24+

## High Complexity Tests

Our in-house tests cover molecular infectious diseases, antibiotic resistance, TBI's, dementia pharmacogenomics (PGx).

Daily

## Sample Pickup

Our courier services will pickup samples from your doorstep.

24 Hrs

## Turnaround Time

Most infectious disease results are delivered within 24 hours, with all other tests ensuring fast and reliable turnaround times.

Dive Deeper with Us to Deliver  
Exceptional Care Together!

**BioCentra**®  
**Diagnostics**™

5600 S Willow Drive Houston, Texas 77035 USA

Phone: +1 (832) 831-3624 (O)

Email: [admin@BioCentra.com](mailto:admin@BioCentra.com)

[www.BioCentraDx.com](http://www.BioCentraDx.com) | [www.TBioScanDx.com](http://www.TBioScanDx.com) | [www.LIMSNNextGen.com](http://www.LIMSNNextGen.com)

